Bank of America Securities Reaffirms Their Hold Rating on Intellia Therapeutics (NTLA)

In a report released today, Alec Stranahan from Bank of America Securities reiterated a Hold rating on Intellia Therapeutics, with a price target of $19.00.

Claim 30% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Stranahan covers the Healthcare sector, focusing on stocks such as Moderna, Novavax, and Day One Biopharmaceuticals. According to TipRanks, Stranahan has an average return of 5.0% and a 49.85% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Intellia Therapeutics with a $20.62 average price target.

Based on Intellia Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $23.02 million and a GAAP net loss of $95.79 million. In comparison, last year the company earned a revenue of $12.87 million and had a GAAP net loss of $128.9 million

Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NTLA in relation to earlier this year. Earlier this month, Eliana Clark, the EVP, CTO of NTLA sold 607.00 shares for a total of $8,364.46.